BR112014023387B1 - Processo de determinação in vitro da susceptibilidade a infecções nosocomiais, utilização da medição in vitro da expressão scd127 e kit para medição in vitro da expressão scd127 - Google Patents

Processo de determinação in vitro da susceptibilidade a infecções nosocomiais, utilização da medição in vitro da expressão scd127 e kit para medição in vitro da expressão scd127 Download PDF

Info

Publication number
BR112014023387B1
BR112014023387B1 BR112014023387-0A BR112014023387A BR112014023387B1 BR 112014023387 B1 BR112014023387 B1 BR 112014023387B1 BR 112014023387 A BR112014023387 A BR 112014023387A BR 112014023387 B1 BR112014023387 B1 BR 112014023387B1
Authority
BR
Brazil
Prior art keywords
scd127
expression
patient
sample
days
Prior art date
Application number
BR112014023387-0A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014023387A2 (enExample
Inventor
Alain LePape
Fabienne Venet
Astrid Villars
Guillaume Monneret
Original Assignee
Biomerieux
Hospices Civils De Lyon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomerieux, Hospices Civils De Lyon filed Critical Biomerieux
Priority to BR122021026851-7A priority Critical patent/BR122021026851B1/pt
Publication of BR112014023387A2 publication Critical patent/BR112014023387A2/pt
Publication of BR112014023387B1 publication Critical patent/BR112014023387B1/pt

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29B—PREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
    • B29B15/00—Pretreatment of the material to be shaped, not covered by groups B29B7/00 - B29B13/00
    • B29B15/08—Pretreatment of the material to be shaped, not covered by groups B29B7/00 - B29B13/00 of reinforcements or fillers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C35/00—Heating, cooling or curing, e.g. crosslinking or vulcanising; Apparatus therefor
    • B29C35/02—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould
    • B29C35/0266—Local curing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C70/00—Shaping composites, i.e. plastics material comprising reinforcements, fillers or preformed parts, e.g. inserts
    • B29C70/04—Shaping composites, i.e. plastics material comprising reinforcements, fillers or preformed parts, e.g. inserts comprising reinforcements only, e.g. self-reinforcing plastics
    • B29C70/06—Fibrous reinforcements only
    • B29C70/10—Fibrous reinforcements only characterised by the structure of fibrous reinforcements, e.g. hollow fibres
    • B29C70/16—Fibrous reinforcements only characterised by the structure of fibrous reinforcements, e.g. hollow fibres using fibres of substantial or continuous length
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C70/00—Shaping composites, i.e. plastics material comprising reinforcements, fillers or preformed parts, e.g. inserts
    • B29C70/04—Shaping composites, i.e. plastics material comprising reinforcements, fillers or preformed parts, e.g. inserts comprising reinforcements only, e.g. self-reinforcing plastics
    • B29C70/28—Shaping operations therefor
    • B29C70/30—Shaping by lay-up, i.e. applying fibres, tape or broadsheet on a mould, former or core; Shaping by spray-up, i.e. spraying of fibres on a mould, former or core
    • B29C70/38—Automated lay-up, e.g. using robots, laying filaments according to predetermined patterns
    • B29C70/382—Automated fiber placement [AFP]
    • B29C70/384—Fiber placement heads, e.g. component parts, details or accessories
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C35/00—Heating, cooling or curing, e.g. crosslinking or vulcanising; Apparatus therefor
    • B29C35/02—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould
    • B29C2035/0211—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould resistance heating
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C53/00—Shaping by bending, folding, twisting, straightening or flattening; Apparatus therefor
    • B29C53/56—Winding and joining, e.g. winding spirally
    • B29C53/58—Winding and joining, e.g. winding spirally helically
    • B29C53/581—Winding and joining, e.g. winding spirally helically using sheets or strips consisting principally of plastics material
    • B29C53/582—Winding and joining, e.g. winding spirally helically using sheets or strips consisting principally of plastics material comprising reinforcements, e.g. wires, threads
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2101/00—Use of unspecified macromolecular compounds as moulding material
    • B29K2101/10—Thermosetting resins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/24—Condition, form or state of moulded material or of the material to be shaped crosslinked or vulcanised
    • B29K2105/243—Partially cured
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Mechanical Engineering (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Composite Materials (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Textile Engineering (AREA)
  • Thermal Sciences (AREA)
  • Robotics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Surgery (AREA)
  • Medical Informatics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Materials Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
BR112014023387-0A 2012-03-23 2013-03-22 Processo de determinação in vitro da susceptibilidade a infecções nosocomiais, utilização da medição in vitro da expressão scd127 e kit para medição in vitro da expressão scd127 BR112014023387B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122021026851-7A BR122021026851B1 (pt) 2012-03-23 2013-03-22 Processo de determinação in vitro da susceptibilidade a infecções nosocomiais

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1252641A FR2988479B1 (fr) 2012-03-23 2012-03-23 Procede de determination de la susceptibilite aux infections nosocomiales
FR1252641 2012-03-23
PCT/FR2013/050624 WO2013140103A1 (fr) 2012-03-23 2013-03-22 Procédé de détermination de la susceptibilité aux infections nosocomiales

Publications (2)

Publication Number Publication Date
BR112014023387A2 BR112014023387A2 (enExample) 2017-06-20
BR112014023387B1 true BR112014023387B1 (pt) 2022-05-17

Family

ID=48237069

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014023387-0A BR112014023387B1 (pt) 2012-03-23 2013-03-22 Processo de determinação in vitro da susceptibilidade a infecções nosocomiais, utilização da medição in vitro da expressão scd127 e kit para medição in vitro da expressão scd127

Country Status (9)

Country Link
US (2) US9823239B2 (enExample)
EP (1) EP2828657B9 (enExample)
JP (2) JP6162788B2 (enExample)
CN (1) CN104246499B (enExample)
AU (1) AU2013237275B2 (enExample)
BR (1) BR112014023387B1 (enExample)
ES (1) ES2573807T3 (enExample)
FR (1) FR2988479B1 (enExample)
WO (1) WO2013140103A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2988479B1 (fr) * 2012-03-23 2014-12-19 Hospices Civils Lyon Procede de determination de la susceptibilite aux infections nosocomiales
FR3010792B1 (fr) * 2013-09-18 2017-03-17 Biomerieux Sa Procede d'evaluation du risque de mortalite chez les patients qui presentent une reponse inflammatoire systemique (sirs) ou des syndromes septiques
FR3044325B1 (fr) * 2015-12-01 2019-05-03 Biomerieux Procede d'evaluation du risque de complications chez les patients qui presentent un syndrome de reponse inflammatoire systemique (sirs)
CN108922620A (zh) * 2018-06-20 2018-11-30 南华大学 一种手术切口感染风险评估系统
FR3112208A1 (fr) * 2020-07-06 2022-01-07 bioMérieux Procédé pour déterminer le risque de survenue d’une infection associée aux soins chez un patient
FR3112209A1 (fr) * 2020-07-06 2022-01-07 bioMérieux Procédé pour déterminer le risque de complication chez un patient
FR3112207A1 (fr) * 2020-07-06 2022-01-07 bioMérieux Procédé pour déterminer le risque de survenue d’une infection associée aux soins chez un patient
FR3112211A1 (fr) * 2020-07-06 2022-01-07 bioMérieux Procédé pour déterminer le risque de survenue d’une infection associée aux soins chez un patient

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
FI915911A0 (fi) * 1989-06-15 1991-12-16 Immunex Corp Interleukin-7-receptorer.
WO2005073164A1 (en) * 2004-01-30 2005-08-11 Peplin Biolipids Pty Ltd Therapeutic and carrier molecules
CN101432740B (zh) * 2004-07-27 2016-08-10 康尔福盛303有限公司 用于测量医院获得性感染发病率的方法
CN102443627B (zh) * 2004-08-10 2014-10-29 加的夫生物学有限公司 用于乳腺癌的预后的试剂盒
DE102008000715B9 (de) * 2008-03-17 2013-01-17 Sirs-Lab Gmbh Verfahren zur in vitro Erfasssung und Unterscheidung von pathophysiologischen Zuständen
UY32038A (es) * 2008-08-08 2010-03-26 Glaxo Wellcome Mfg Pte Ltd Inmunoblobulinas anti-cd127 y sus usos
CA2740191A1 (en) * 2008-10-09 2010-04-15 Thomas Ryan A method of estimating risk of severe sepsis in an individual with infection
MX2011007624A (es) * 2009-01-19 2011-10-12 Hospices Civils Lyon Metodos para determinar la susceptibilidad de contraer una infeccion nosocomial en el paciente y para establecer el pronostico de la evolucion del sindrome septico.
FR2941240B1 (fr) * 2009-01-19 2013-05-10 Biomerieux Sa Procede pour determiner la sensibilite d'un patient a contracter une infection nosocomiale.
FR2988479B1 (fr) * 2012-03-23 2014-12-19 Hospices Civils Lyon Procede de determination de la susceptibilite aux infections nosocomiales
BR112015016018A2 (pt) * 2013-01-03 2017-07-11 Unilever Nv composição para cuidado dos cabelos

Also Published As

Publication number Publication date
JP6162788B2 (ja) 2017-07-12
EP2828657B9 (fr) 2016-08-24
BR112014023387A2 (enExample) 2017-06-20
CN104246499A (zh) 2014-12-24
JP2017198692A (ja) 2017-11-02
AU2013237275B2 (en) 2018-07-05
ES2573807T3 (es) 2016-06-10
FR2988479B1 (fr) 2014-12-19
EP2828657B1 (fr) 2016-03-16
WO2013140103A1 (fr) 2013-09-26
CN104246499B (zh) 2017-05-10
EP2828657A1 (fr) 2015-01-28
US20150064728A1 (en) 2015-03-05
US9823239B2 (en) 2017-11-21
JP2015513097A (ja) 2015-04-30
AU2013237275A1 (en) 2014-10-02
US10725029B2 (en) 2020-07-28
JP6458087B2 (ja) 2019-01-23
US20180111342A1 (en) 2018-04-26
FR2988479A1 (fr) 2013-09-27

Similar Documents

Publication Publication Date Title
US12379384B2 (en) Method of diagnosing cancer and diagnosis kit using measurement of NK cell activity
ES2573807T3 (es) Procedimiento de determinación de susceptibilidad a las infecciones nosocomiales
Foell et al. Phagocyte‐specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease
ES2434996T3 (es) Métodos de pronóstico en enfermedad renal crónica
Kushner Acute phase reactants
ES2738212T3 (es) Procedimiento de predicción de un pronóstico de septicemia
Singal et al. Cellular abnormalities and emerging biomarkers in alcohol-associated liver disease
US20200256876A1 (en) KIT FOR IN VITRO OR EX VIVO MEASUREMENT OF THE EXPRESSION OF sCD127 IN A BIOLOGICAL SAMPLE
Cords et al. Frequency of IRF5+ dendritic cells is associated with the TLR7-induced inflammatory cytokine response in SARS-CoV-2 infection
WO2018046522A1 (en) Methods for predicting the survival time in a subject
BR122021026851B1 (pt) Processo de determinação in vitro da susceptibilidade a infecções nosocomiais
US20230400464A1 (en) Method for assessing the severity of sars
Obaid et al. Association of Terminal Complement Complex (TCC), Prostaglandin (PGj2) among Patient with First Episode Psychosis (Case-Control Study)
Shirakawa The Sepsis Marker “Presepsin”: Biochemistry and Clinical Diagnosis
Lyu Role of anti-DFS70 antibodies in idiopathic interstitial pneumonia and in connective tissue disease associated interstitial lung disease
Peschel PRECLINICAL EVALUATION OF PCT/CGRP–RECEPTOR ANTAGONISM AS A NOVEL STRATEGY FOR SEPSIS TREATMENT
Reyers CRP as a test for assessing and monitoring systemic inflammation.
AL-SHAMMA et al. SERUM NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (NGAL) AS A PREDICTIVE BIOMARKER OF KIDNEY INJURY IN RENAL TRANSPLANTED PATIENTS and CHRONIC KIDNEY

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/03/2013, OBSERVADAS AS CONDICOES LEGAIS

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 12A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2822 DE 04-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.